<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id>
      <journal-id journal-id-type="publisher-id">eins</journal-id>
      <journal-title-group>
        <journal-title>Einstein</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1679-4508</issn>
      <issn pub-type="epub">2317-6385</issn>
      <publisher>
        <publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26398363</article-id>
      <article-id pub-id-type="pmc">4872920</article-id>
      <article-id pub-id-type="publisher-id">S1679-45082015RC2992</article-id>
      <article-id pub-id-type="doi">10.1590/S1679-45082015RC2992</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Male urethral sarcoma: a case report and literature review</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nogueira</surname>
            <given-names>Magno Almeida</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>dos Santos</surname>
            <given-names>Guilherme Campelo Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Roberto Iglesias</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campos</surname>
            <given-names>Octavio Henrique Arcos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dall&#x2019;Oglio</surname>
            <given-names>Marcos Francisco</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sant&#x2019;Anna</surname>
            <given-names>Alexandre Crippa</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Hospital do Servidor P&#xFA;blico Municipal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <aff id="aff2"><label>2</label>Hospital das Cl&#xED;nicas, Faculdade de Medicina, Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brazil.</aff>
      <author-notes>
        <corresp><label>Corresponding author</label>: Magno Almeida Nogueira &#x2013; Hospital do Servidor P&#xFA;blico Municipal &#x2013; Rua Castro Alves, 60 &#x2013; Setor Urologia, 6th floor, room 15 &#x2013; Liberdade &#x2013; Zip code: 01532-000 &#x2013; S&#xE3;o Paulo, SP, Brazil &#x2013; Phone: (55 11) 3397-7700 &#x2013; E-mail: <email>magno.nogueira@icloud.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Mar</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Mar</season>
        <year>2016</year>
      </pub-date>
      <volume>14</volume>
      <issue>1</issue>
      <fpage>64</fpage>
      <lpage>66</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>9</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>Urethral tumors are rare and aggressive. They usually affect men (2:1) and occur more commonly in white (85% of cases). Soft tissue sarcomas are a heterogeneous group of tumors that arise from embryonic mesoderm. It represents 1% of all cases of urinary tract malignancies and rarely primary affect the ureter. We report a case of male urethral sarcoma. To date, only two similar cases have been published in literature.</p>
      </abstract>
      <kwd-group>
        <kwd>Sarcoma</kwd>
        <kwd>Urethral neoplasms</kwd>
        <kwd>Hematuria</kwd>
        <kwd>Case reports</kwd>
      </kwd-group>
      <counts>
        <fig-count count="6"/>
        <table-count count="2"/>
        <equation-count count="0"/>
        <ref-count count="10"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Urethral tumors are rare and aggressive, they occur more frequently in men (2:1) and often affect whites (85% of cases).<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
      <p>Approximately 600 cases of urethral cancer in men are reported in the world literature. The epidermoid carcinoma is the most common histological type (80% of cases), followed by transitional cell cancer (15%) and adenocarcinomas (5%). The most affected local is bulbomembranous urethra followed by penile and prostatic urethra.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> Urethral cancer is often diagnosed between the age of 50-79 years.<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref></sup>
</p>
      <p>The disease has an unspecific presentation and, according to some case series reported, the most common symptoms are hematuria, dysuria, urinary retention and urinary incontinence.<sup><xref rid="B4" ref-type="bibr">4</xref></sup>
</p>
      <p>Soft tissue sarcomas constitute a heterogenous group of tumors that appear in the embryonic mesoderm and account for 1 to 2% of all malignant disease of the urinary tract.<sup><xref rid="B5" ref-type="bibr">5</xref></sup>
</p>
      <p>In general sarcomas most common forms are liposarcoma, malignant histiocytoma and leiomyosarcoma.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> The most frequent types of genitourinary sarcomas are leiomyosarcoma, liposarcoma and rhabdomyosarcoma.<sup><xref rid="B6" ref-type="bibr">6</xref></sup>
</p>
      <p>We report a case of sarcoma of the male urethra that, so far, only two similar cases have been reported in the literature.<sup><xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref></sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>We report a case of 73-year-old white man with history of myocardial infarction (MI), which occurred 3 years earlier, and who was diagnosed with systemic arterial hypertension. He was not a smoker and did not consume alcohol. The patient&#x2019;s complain was macroscopic hematuria that started intermittent and then continuing that lasted for 1 year.</p>
      <p>At physical examination no visceromegaly or lymphadenomegaly was observed. The urological exam showed urethrorrhagia without sings of macroscopic lesions. Rectal examination revealed a 30g prostate without nodularity and painless. Patient had normal blood count and coagulogram, early-onset chronic renal failure (urea was 49mg/dL and creatinine was 1.5mg/dL). Total abdominal ultrasound was normal and pelvis examination with contrast showed an extensive injury in posterior urethra that invaded the prostate, bladder and perivesical tissue (<xref ref-type="fig" rid="f01">Figure 1</xref>), but no changes were seen in the upper urinary tract or distant metastasis. The cystoscopy showed a brown injury in the posterior urethra (membranous and prostatic). A biopsy was performed and the result revealed a mesenchymal neoplasia with myxoid degeneration area and high mitotic index.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Nuclear magnetic ressonance of the pelvis showing the urethral tumor (arrow)</title></caption><graphic xlink:href="1679-4508-eins-14-1-0064-gf01"/></fig>
</p>
      <p>The patient underwent a cystoprostatectomy with removal of the testicles, pelvic lymphadenectomy and ureteroileostomy using the Bricker method (<xref ref-type="fig" rid="f02">Figure 2</xref>). After the procedure the patient had a good progress, recovery of physiological functions and adequate diuresis. However, on the 10th postoperative day he died after a new episode of MI.</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Posterior urethral sarcoma (indicated with arrows). Thickening and hardening of the affected area</title></caption><graphic xlink:href="1679-4508-eins-14-1-0064-gf02"/></fig>
</p>
      <p>The anatomopathological study showed a high histological degree pleomorphic sarcoma, measuring approximately 20.0cm, in the bulbar urethra with neoplasia affecting the bladder base, periprostatic region, seminal vesicles, base of the penis and cavernous bodies (<xref ref-type="fig" rid="f03">Figure 3</xref>). The urethral tumor had high cellularity, high mitotic index, 30% necrosis of tumor volume and intense anaplastic effect. The perivescial surgical margins and the right ureter was compromised. The left urethral margin was free of malignancy. No metastasis was observed in 15 dissected lymph nodes in the pelvic lymphadenectomy. Mesenchymal cells vimentin and desmin were positive in the immunohistochemical analysis, but other markers such as cytokeratin, S-100, CD 117, CD 30, CD 20, CD 3 and CD 56 were negative. This finding excluded other origins such as epithelial, hematological and neural tumors.</p>
      <p>
<fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><title>(A) High degree urethral sarcoma; (B) Immunohistochemical analysis that revealed strong positivity of vimentin; (C) Urethral tumor also showing positivity for desmin</title></caption><graphic xlink:href="1679-4508-eins-14-1-0064-gf03"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Survival rates of patients with genitourinary sarcomas is worse compared with other soft tissue regions.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Prognosis is relatively poor and can be explained by the high proportion seen in high degree tumors, large proportion of patients with metastatic disease, large tumor and the area affected. In addition, the rarity and heterogeneity of genitourinary sarcomas can explain the great variability in clinical progress in different subgroups.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
      <p>Dissemination of urethral cancer follows the anatomic subdivision. The anterior urethra has a lymphatic drainage system for superficial and deep inguinal region. Posterior urethra drains the lymphatic ganglion of external iliac artery, hypo gastric, and internal obturator muscle.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
      <p>Late diagnosis is seen in one third of patients with inguinal lymphatic ganglion metastasis and in 20% of those with pelvic ganglion metastasis. The most common distant metastasis appears in lungs, liver and bones.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
      <p>Anterior tumors present better prognosis reaching up to 60% in 5 years. Tumors &lt;2cm have 81% of survival for 5 years. On the other hand, tumors of posterior urethra have 10% survival rate for 5 years if &lt;2cm, 37% of survival for 5 years when presenting tumors 2 to 4cm and only 7% when &gt;4cm. In general, in a stage higher than T2 the survival rate for 5 years is observed in &lt;26%.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
      <p>Histological characteristics of genito-urinary sarcomas are quite variable. Most of them present high degree of differentiation and isolated focus of squamous metaplasia.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
      <p>To date, only two cases of sarcoma of the male urethra have been described in the literature. The first cases was a 78-year-old man with ulcerative injury in urethra.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> The second was a 65-year-old man who underwent a perineal uretrostomy to treat a distal urethral stenosis <sup><xref rid="B8" ref-type="bibr">8</xref></sup>(<xref ref-type="table" rid="t1">Chart 1</xref>).</p>
      <p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Chart 1</label><caption><title>Case reported in the literature about sarcoma of the male urethra</title></caption><table frame="hsides" rules="groups"><colgroup width="17%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Patient</th><th rowspan="1" colspan="1">Age (years)</th><th rowspan="1" colspan="1">Local</th><th rowspan="1" colspan="1">Size</th><th rowspan="1" colspan="1">Treatment</th><th rowspan="1" colspan="1">Progress</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1<sup><underline>o</underline></sup> patient<sup>(7)</sup>
</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">Posterior urethra</td><td align="center" rowspan="1" colspan="1">Not evaluated</td><td align="center" rowspan="1" colspan="1">Vesical drainage</td><td align="center" rowspan="1" colspan="1">Not evaluated</td></tr><tr><td rowspan="1" colspan="1">2<sup><underline>o</underline></sup> patient<sup>(8)</sup>
</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">Bulbar urethra</td><td align="center" rowspan="1" colspan="1">6cm</td><td align="center" rowspan="1" colspan="1">Pelvic exenteration, chemotherapy and adjuvant radiotherapy</td><td align="center" rowspan="1" colspan="1">Death after 7 months</td></tr></tbody></table></table-wrap>
</p>
      <p>The main treatment for urethral cancer is surgical excision. Anterior urethral cancer has a better surgical control and prognosis than the posterior urethral that often present association with local invasion and distant extensive metastasis.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
      <p>More conservative procedures can be acceptable in selected cases with superficial injuries, papillary tumors or low degree tumors.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> In case of infiltrating tumors of sponge&#x2019;s body located in distal half of the penis, the partial penectomy can be a treatment option.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> If the disease is invasive, extending for more than half of the penile urethra, the radiotherapy can be a treatment option for unresectable lesions.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
      <p>Radiotherapy and chemotherapy can be applied to tumors located in bulbocavernosus urethra even for those occurring in the prostatic urethra. In cases of advanced injuries, the treatment applied is extensive surgery with chemotherapy and adjuvant radiotherapy. The isolated chemotherapy is the only option for cases of extensive metastasis.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
      <p>In our case the diagnosis was advanced urethral sarcoma (T4N0M0), with positive surgical margin in a clinically severe patient with cardiomyopathy that led to an unfavorable outcome. The MI presented by the patient in early postoperative period did not enable the adjuvant therapy with radiotherapy and chemotherapy. It becomes clear that these tumors are extremely aggressive and have poor prognosis.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swartz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <article-title>Incidence of primary urethral carcinoma in the United States</article-title>
          <source>Urology</source>
          <year>2006</year>
          <volume>68</volume>
          <issue>6</issue>
          <fpage>1164</fpage>
          <lpage>1168</lpage>
          <pub-id pub-id-type="pmid">17141838</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Walsh</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Retik</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <chapter-title>Surgery of penile and urethral carcinoma</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>McDougal</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Wein</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Kavoussi</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Novick</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Partin</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>CA</given-names>
            </name>
            <etal>et al</etal>
            <role>editors</role>
          </person-group>
          <source>Campbell&#xB4;s Urology</source>
          <edition>10th ed</edition>
          <publisher-loc>Philadelphia</publisher-loc>
          <publisher-name>WB Sauders</publisher-name>
          <year>2012</year>
          <fpage>946</fpage>
          <lpage>951</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stojadinovic</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Jaques</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables</article-title>
          <source>J Clin Oncol</source>
          <year>2002</year>
          <volume>20</volume>
          <issue>21</issue>
          <fpage>4344</fpage>
          <lpage>4352</lpage>
          <pub-id pub-id-type="pmid">12409334</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Touijer</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Dalbagni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Role of voided urine cytology in diagnosing primary urethral carcinoma</article-title>
          <source>Urology</source>
          <year>2004</year>
          <volume>63</volume>
          <issue>1</issue>
          <fpage>33</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">14751342</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Srinivas</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sogani</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Hajdu</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Whitmore</surname>
              <given-names>WF</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Sarcomas of the kidney</article-title>
          <source>J Urol</source>
          <year>1984</year>
          <volume>132</volume>
          <issue>1</issue>
          <fpage>13</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">6328050</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sexton</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Lance</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Reyes</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Pisters</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Pisters</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
          <article-title>Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience</article-title>
          <source>J Urol</source>
          <year>2001</year>
          <volume>166</volume>
          <issue>2</issue>
          <fpage>521</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="pmid">11458058</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mark</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Primary sarcoma of the male urethra: report of a case</article-title>
          <source>Ann Surg</source>
          <year>1992</year>
          <volume>55</volume>
          <issue>3</issue>
          <fpage>416</fpage>
          <lpage>418</lpage>
          <pub-id pub-id-type="pmid">17862819</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahallal</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tazi</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Khallouk</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tazi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Benlemlih</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>El Fassi</surname>
              <given-names>MJ</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Primary leiomyosarcoma of the male urethra: a case report</article-title>
          <source>Cases J</source>
          <year>2009</year>
          <volume>2</volume>
          <elocation-id/>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Judson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Soft-tissue sarcomas in adults</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <issue>7</issue>
          <fpage>701</fpage>
          <lpage>711</lpage>
          <comment>Review</comment>
          <pub-id pub-id-type="pmid">16107623</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dotan</surname>
              <given-names>ZA</given-names>
            </name>
            <name>
              <surname>Tal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Golijanin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Antonescu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>MF</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience</article-title>
          <source>J Urol</source>
          <year>2006</year>
          <volume>176</volume>
          <issue>5</issue>
          <fpage>2033</fpage>
          <lpage>2038</lpage>
          <comment>discussion 2038-9</comment>
          <pub-id pub-id-type="pmid">17070247</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="TRpt" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Sarcoma de uretra masculina: relato de caso e revis&#xE3;o de literatura</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nogueira</surname>
            <given-names>Magno Almeida</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Guilherme Campelo Lopes dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Roberto Iglesias</given-names>
          </name>
          <xref ref-type="aff" rid="aff2002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Campos</surname>
            <given-names>Octavio Henrique Arcos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1002">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dall&#x2019;Oglio</surname>
            <given-names>Marcos Francisco</given-names>
          </name>
          <xref ref-type="aff" rid="aff2002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sant&#x2019;Anna</surname>
            <given-names>Alexandre Crippa</given-names>
          </name>
          <xref ref-type="aff" rid="aff2002">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1002"><label>1</label> Hospital do Servidor P&#xFA;blico Municipal de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <aff id="aff2002"><label>2</label> Hospital das Cl&#xED;nicas, Faculdade de Medicina, Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP, Brasil.</aff>
      <author-notes>
        <corresp> Autor correspondente: Magno Almeida Nogueira &#x2013; Hospital do Servidor P&#xFA;blico Municipal &#x2013; Rua Castro Alves, 60 &#x2013; Setor Urologia, 6<sup><underline>o</underline></sup> andar, sala 15 &#x2013; Liberdade &#x2013; CEP: 01532-000 &#x2013; S&#xE3;o Paulo, SP, Brasil Tel.: (11) 3397-7700 &#x2013; E-mail: magno.nogueira@icloud.com </corresp>
      </author-notes>
      <abstract>
        <title>RESUMO</title>
        <p>Os tumores de uretra s&#xE3;o muito raros e bastante agressivos. Acometem mais frequentemente homens (2:1) e s&#xE3;o mais comuns na ra&#xE7;a branca (85% dos casos). Os sarcomas de tecidos moles s&#xE3;o um grupo heterog&#xEA;neo de tumores que surgem a partir da mesoderme embrion&#xE1;ria e representam 1% de todos os casos de doen&#xE7;a maligna urin&#xE1;ria, raramente acometendo a uretra primariamente. Relamos aqui um caso extremamente raro de sarcoma uretral masculino com somente dois semelhantes publicados na literatura.</p>
      </abstract>
      <kwd-group>
        <kwd>Sarcoma</kwd>
        <kwd>Neoplasias uretrais</kwd>
        <kwd>Hemat&#xFA;ria</kwd>
        <kwd>Relatos de casos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>INTRODU&#xC7;&#xC3;O</title>
        <p>Os tumores de uretra s&#xE3;o muito raros e bastante agressivos. Acometem mais frequentemente homens (2:1) e s&#xE3;o mais comuns na ra&#xE7;a branca (85% dos casos).<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
        <p>S&#xE3;o relatados aproximadamente 600 casos de c&#xE2;ncer uretral masculino na literatura mundial. O carcinoma epidermoide &#xE9; o tipo histol&#xF3;gico mais comum (80% dos casos), seguido do carcinoma de c&#xE9;lulas transicionais (15%) e dos adenocarcinomas (5%). O local mais acometido &#xE9; a uretra bulbomembranosa, seguida da uretra peniana e prost&#xE1;tica.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> A faixa et&#xE1;ria do diagn&#xF3;stico de tumor uretral maligno &#xE9; de 50 a 79 anos.<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref></sup>
</p>
        <p>A doen&#xE7;a tem apresenta&#xE7;&#xE3;o inicial inespec&#xED;fica e, de acordo com algumas s&#xE9;ries de casos relatados, os sintomas mais comuns s&#xE3;o hemat&#xFA;ria, dis&#xFA;ria, reten&#xE7;&#xE3;o urin&#xE1;ria e incontin&#xEA;ncia urin&#xE1;ria.<sup><xref rid="B4" ref-type="bibr">4</xref></sup>
</p>
        <p>Os sarcomas de tecidos moles s&#xE3;o um grupo heterog&#xEA;neo de tumores que surgem a partir da mesoderme embrion&#xE1;ria, que representa 1 a 2% de todos os casos de doen&#xE7;a maligna urin&#xE1;ria.<sup><xref rid="B5" ref-type="bibr">5</xref></sup>
</p>
        <p>Os sarcomas, em geral, possuem como formas mais comum o lipossarcoma, seguido do histiocitoma maligno e do leiomiossarcoma.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Em rela&#xE7;&#xE3;o aos sarcomas geniturin&#xE1;rios, o tipo mais frequente &#xE9; o leiomiossarcoma, seguido do lipossarcoma e do rabdomiossarcoma.<sup><xref rid="B6" ref-type="bibr">6</xref></sup>
</p>
        <p>Relatamos e discutimos aqui um caso de sarcoma de uretra masculino, que, por sua raridade, tem apenas dois casos relatados.<sup><xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref></sup>
</p>
      </sec>
      <sec>
        <title>RELATO DE CASO</title>
        <p>Paciente de 73 anos, do sexo masculino, ra&#xE7;a branca, com hist&#xF3;ria de infarto agudo do mioc&#xE1;rdico (IAM) h&#xE1; 3 anos e diagn&#xF3;stico de hipertens&#xE3;o arterial sist&#xEA;mica, sem hist&#xF3;ria de tabagismo e etilismo. Apresentou-se com queixa de hemat&#xFA;ria macrosc&#xF3;pica, inicialmente intermitente e, posteriormente, cont&#xED;nua, de in&#xED;cio h&#xE1; 1 ano.</p>
        <p>No exame f&#xED;sico, n&#xE3;o foram notadas visceromegalias ou linfonodomegalias. Ao exame urol&#xF3;gico, notou-se uretrorragia, sem sinais de les&#xF5;es macrosc&#xF3;picas. O toque retal revelou pr&#xF3;stata de 30g sem n&#xF3;dulos, indolor. O paciente apresentava hemograma e coagulograma normais, fun&#xE7;&#xE3;o renal com doen&#xE7;a renal cr&#xF4;nica incipiente (ureia 49mg/dL e creatinina 1,5mg/dL). O ultrassom de abdome total era normal, por&#xE9;m a resson&#xE2;ncia nuclear magn&#xE9;tica de abdome e pelve com contraste evidenciou les&#xE3;o extensa em uretra posterior, que invadia pr&#xF3;stata, bexiga e tecido perivesical (<xref ref-type="fig" rid="f01002">Figura 1</xref>), sem altera&#xE7;&#xE3;o de trato urin&#xE1;rio alto ou met&#xE1;stases a dist&#xE2;ncia. A uretrocistoscopia demonstrou les&#xE3;o acastanhada na uretra posterior (membranosa e prost&#xE1;tica), que, submetida &#xE0; bi&#xF3;psia, demonstrou neoplasia de padr&#xE3;o mesenquimal, com &#xE1;reas de degenera&#xE7;&#xE3;o mixoide e alto &#xED;ndice mit&#xF3;tico.</p>
        <p>
<fig id="f01002" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Resson&#xE2;ncia nuclear magn&#xE9;tica de pelve demonstrando tumor acometendo uretra (seta)</title></caption><graphic xlink:href="1679-4508-eins-14-1-0064-gf01-pt"/></fig>
</p>
        <p>O paciente foi submetido &#xE0; cistoprostatectomia com emascula&#xE7;&#xE3;o, linfadenectomia p&#xE9;lvica e ureteroileostomia &#xE0; Bricker (<xref ref-type="fig" rid="f02002">Figura 2</xref>). Apresentava boa evolu&#xE7;&#xE3;o com recupera&#xE7;&#xE3;o das fun&#xE7;&#xF5;es fisiol&#xF3;gicas e diurese adequada; todavia, apresentou novo epis&#xF3;dio de IAM no 10<sup>o</sup> dia p&#xF3;s-operat&#xF3;rio evoluindo a &#xF3;bito.</p>
        <p>
<fig id="f02002" orientation="portrait" position="float"><label>Figura 2</label><caption><title>Sarcoma da uretra posterior (indicado pelas setas). Clinicamente, notavam-se espessamento e endurecimento da regi&#xE3;o acometida</title></caption><graphic xlink:href="1679-4508-eins-14-1-0064-gf02-pt"/></fig>
</p>
        <p>O estudo anatomopatol&#xF3;gico evidenciou sarcoma pleom&#xF3;rfico de uretra bulbar de alto grau histol&#xF3;gico, com neoplasia acometendo base de bexiga, regi&#xE3;o periprost&#xE1;tica, ves&#xED;culas seminais, base de p&#xEA;nis e corpos cavernosos, com maior di&#xE2;metro aproximado de 20,0cm (<xref ref-type="fig" rid="f03002">Figura 3</xref>). O tumor uretral apresentou alta celularidade, alto &#xED;ndice mit&#xF3;tico, necrose em 30% do volume tumoral e intensa anaplasia. Margens cir&#xFA;rgicas perivesical e ureteral direita comprometidas. Margem ureteral esquerda livre. Aus&#xEA;ncia de met&#xE1;stases para 15 linfonodos dissecados na linfadenectomia il&#xED;aca. Na imuno-histoqu&#xED;mica, as pesquisas para os marcadores mesenquimais desmina e vimentina vieram positivos, enquanto pesquisas de outros marcadores, como citoqueratina, S-100, CD 117, CD 30, CD 20, CD 3 e CD 56, foram negativos, excluindo outras origens como epitelial, hematol&#xF3;gica e tumores neurais.</p>
        <p>
<fig id="f03002" orientation="portrait" position="float"><label>Figura 3</label><caption><title>(A) Sarcoma uretral de alto grau; (B) Imuno-histoqu&#xED;mica que revelou forte positividade de vimentina; (C) O tumor uretral tamb&#xE9;m apresentava positividade para desmina</title></caption><graphic xlink:href="1679-4508-eins-14-1-0064-gf03-pt"/></fig>
</p>
      </sec>
      <sec>
        <title>DISCUSS&#xC3;O</title>
        <p>A taxa de sobreviv&#xEA;ncia de doentes com sarcoma de geniturin&#xE1;rio &#xE9; pior em rela&#xE7;&#xE3;o &#xE0;queles com sarcoma de tecidos moles em outras localiza&#xE7;&#xF5;es.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> O progn&#xF3;stico relativamente pobre pode ser explicado pela maior propor&#xE7;&#xE3;o de tumores de grau elevado, a maior propor&#xE7;&#xE3;o de pacientes que se apresentam com doen&#xE7;a metast&#xE1;tica, um maior tamanho tumoral e o local anat&#xF4;mico. Al&#xE9;m disso, a raridade e a heterogeneidade dos sarcomas geniturin&#xE1;rios podem significar grandes diferen&#xE7;as de evolu&#xE7;&#xE3;o cl&#xED;nica nos v&#xE1;rios subgrupos.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
        <p>As vias de dissemina&#xE7;&#xE3;o do carcinoma uretral seguem sua subdivis&#xE3;o anat&#xF4;mica. A uretra anterior possui drenagem linf&#xE1;tica para regi&#xE3;o inguinal superficial e profunda. A uretra posterior drena para os g&#xE2;nglios linf&#xE1;ticos da art&#xE9;ria il&#xED;aca externa e hipog&#xE1;strica, e do m&#xFA;sculo obturador interno.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
        <p>Em um ter&#xE7;o dos pacientes, o diagn&#xF3;stico &#xE9; tardio, com met&#xE1;stases para g&#xE2;nglios linf&#xE1;ticos inguinais, e em 20% para os g&#xE2;nglios p&#xE9;lvicos. Os locais de met&#xE1;stases a dist&#xE2;ncia mais comum s&#xE3;o pulm&#xE3;o, f&#xED;gado e ossos.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
        <p>Os tumores anteriores s&#xE3;o de melhor progn&#xF3;stico, chegando a 60% em 5 anos. Os tumores &lt;2cm t&#xEA;m sobrevida de 81% em 5 anos. Em contrapartida, tumores da uretra posterior possuem taxa de 10% de sobrevida em 5 anos se &lt;2cm, 37% de sobrevida em 5 anos quando de 2 a 4cm de tamanho e apenas 7% quando &gt;4cm. Acima do est&#xE1;dio T2, costumam apresentar uma taxa de sobrevida &lt;26% em 5 anos.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
        <p>As caracter&#xED;sticas histol&#xF3;gicas dos sarcomas urin&#xE1;rios s&#xE3;o bastante variadas. A maioria cont&#xE9;m alto grau de diferencia&#xE7;&#xE3;o com focos isolados de metaplasia escamosa.<sup><xref rid="B10" ref-type="bibr">10</xref></sup>
</p>
        <p>Em rela&#xE7;&#xE3;o aos sarcomas de uretra masculina, somente dois casos foram descritos na literatura. O primeiro caso &#xE9; de um homem de 78 anos com uma les&#xE3;o ulcerada na uretra.<sup><xref rid="B7" ref-type="bibr">7</xref></sup>O segundo foi de um homem de 65 anos com uretrostomia perineal para tratamento de estenose uretral distal<sup><xref rid="B8" ref-type="bibr">8</xref></sup>(<xref ref-type="table" rid="t1002">Quadro 1</xref>).</p>
        <p>
<table-wrap id="t1002" orientation="portrait" position="float"><label>Quadro 1</label><caption><title>Casos relatados na literatura de sarcoma de uretra no sexo masculino</title></caption><table frame="hsides" rules="groups"><colgroup width="17%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Paciente</th><th rowspan="1" colspan="1">Idade (anos)</th><th rowspan="1" colspan="1">Localiza&#xE7;&#xE3;o</th><th rowspan="1" colspan="1">Tamanho</th><th rowspan="1" colspan="1">Tratamento</th><th rowspan="1" colspan="1">Evolu&#xE7;&#xE3;o</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1<sup><underline>o</underline></sup> paciente<sup>(7)</sup>
</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">Uretra posterior</td><td align="center" rowspan="1" colspan="1">N&#xE3;o avaliado</td><td align="center" rowspan="1" colspan="1">Drenagem vesical</td><td align="center" rowspan="1" colspan="1">N&#xE3;o avaliado</td></tr><tr><td rowspan="1" colspan="1">2<sup><underline>o</underline></sup> paciente<sup>(8)</sup>
</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">Uretra bulbar</td><td align="center" rowspan="1" colspan="1">6cm</td><td align="center" rowspan="1" colspan="1">Exantera&#xE7;&#xE3;o p&#xE9;lvica, quimioterapia e radioterapia adjuvante</td><td align="center" rowspan="1" colspan="1">&#xD3;bito ap&#xF3;s 7 meses</td></tr></tbody></table></table-wrap>
</p>
        <p>A principal forma de tratamento &#xE9; a excis&#xE3;o cir&#xFA;rgica. O carcinoma de uretra anterior possui melhor controle cir&#xFA;rgico e melhor progn&#xF3;stico em rela&#xE7;&#xE3;o ao da uretra posterior, que apresenta frequente associa&#xE7;&#xE3;o de invas&#xE3;o local e extensa met&#xE1;stase a dist&#xE2;ncia.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
        <p>Procedimentos mais conservadores podem ser aceit&#xE1;veis em doentes selecionados com les&#xF5;es superficiais, tumores papilares ou de baixo grau.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>No caso de tumores infiltrantes do corpo esponjoso localizados em metade distal do p&#xEA;nis, pode-se tentar uma penectomia parcial.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>Se a doen&#xE7;a for invasiva, estendendo-se por mais da metade da uretra peniana, a penectomia total &#xE9; necess&#xE1;ria.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
        <p>Radioterapia e quimioterapia s&#xE3;o op&#xE7;&#xF5;es como tratamento prim&#xE1;rio ou de forma adjuvante. Em tumores localizados na uretra peniana, a radioterapia entra como tratamento opcional em les&#xF5;es irressec&#xE1;veis. Naqueles localizados na uretra bulbo-carvenosa, a radioterapia e a quimioterapia neoadjuvante podem ser realizadas, o mesmo ocorrendo em tumores localizados na uretra prost&#xE1;tica. Em casos de les&#xF5;es avan&#xE7;adas, o tratamento realizado &#xE9; cirurgia extensa com quimioterapia e radioterapia adjuvante e, nos casos com met&#xE1;stase extensa, quimioterapia isolada &#xE9; a &#xFA;nica op&#xE7;&#xE3;o.<sup><xref rid="B2" ref-type="bibr">2</xref></sup>
</p>
        <p>No caso apresentado, o diagn&#xF3;stico era de sarcoma uretral avan&#xE7;ado (T4N0M0), com margem cir&#xFA;rgica positiva em um paciente com miocardiopatia clinicamente grave, resultando em desfecho desfavor&#xE1;vel. O IAM apresentado pelo paciente no per&#xED;odo p&#xF3;s-operat&#xF3;rio precoce inviabilizou o tratamento adjuvante com radioterapia e quimioterapia. Fica evidente que esses tumores s&#xE3;o extremamente agressivos e de mau progn&#xF3;stico.</p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
